NCT00848042已完成不适用
A Pilot Study of AuroLase(tm) Therapy in Patients With Refractory and/or Recurrent Tumors of the Head and Neck
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 11
- 试验地点
- 4
- 主要终点
- Number of Participants With Any Adverse Device Effects Considered Attributable to AuroShell Particle Administration
研究概览
简要总结
This is an open-label, multicenter, single-dose pilot study of AuroLase(TM) Therapy in the treatment of patients with refractory and/or recurrent tumors of the head and neck. Three (3) treatment groups of five (5) patients each will be enrolled and observed for six (6) months following treatment. Each group will receive a single dose of AuroShell(TM) particles followed by one or more interstitial illuminations with an 808nm laser. Particle dose and laser power may be increased in each dosing group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 130 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have documented histological or cytological evidence of tumor(s) of the head and neck
- •Patients must have one or more refractory and/or recurrent tumors of the head and neck which have at least one dimension with longest diameter 15 mm using conventional techniques or 10 mm with spiral CT scan.
- •Target lesions should be accessible to examination (examination by fiber optic nasopharyngoscopy or laryngoscopy is permitted) and to biopsy.
- •Each index lesion should be large enough to provide at least 6 mg of tumor tissue by biopsy (such as an 18 gauge Tru-Cut needle biopsy 1cm in length or similar technique) for assessment by neutron activation analysis.
- •Tumors must be measurable according to RECIST criteria
- •Patients must be ≥ 18 years of age
- •Patients must have ECOG Performance Score of 0, 1 or 2 (see Appendix 3)
- •Patients or their legal representative must be able to read, understand and sign an informed consent
- •Adequate renal function as evidenced by serum creatinine ≤ 2.0 mg/dL
- •Adequate hepatic function as evidenced by: Serum total bilirubin ≤ 2.0 mg/dL, Alkaline phosphatase ≤ 2X the ULN for the reference lab, SGOT/SGPT ≤ 2X the ULN for the reference lab
- •Women of childbearing potential must agree to use an effective form of contraception during the study and for 90 days following treatment (an effective form of contraception is an oral contraceptive or a double barrier method). Women who are NOT of childbearing potential are those who have undergone a bilateral oophorectomy or who have undergone menopause, defined as an absence of a menstrual cycle for 12 consecutive months.
- •Negative pregnancy test for women of childbearing potential.
排除标准
- •Patients with known hypersensitivity to any of the components of the PEGylated AuroShell suspension (polyethylene glycol, gold)
- •Patients who are receiving concurrent investigational therapy or who have received investigational therapy within a period of 5 half-lives of the investigational therapy in question prior to the day of dosing with the PEGylated AuroShell particles (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication)
- •Patients who are pregnant and/or lactating
- •Patients with evidence of an active bacterial infection or with a fever ≥ 38.5 ºC (101.3 ºF) within 3 days of the first scheduled day of dosing
- •Patients who have undergone splenectomy
- •Patient who has had a course of radiotherapy in the treatment area within the past 30 days.
- •Patient who has had a course of chemotherapy or other anti-neoplastic therapy in the past 30 days.
- •Patient who has had surgery within 2 cm of the treatment area within the past two weeks.
- •Life expectancy of less than 3 months.
- •Any other medical condition, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results.
结局指标
主要结局
Number of Participants With Any Adverse Device Effects Considered Attributable to AuroShell Particle Administration
时间窗: up to 6 months
Includes all participants that experienced an adverse device effect that were rated probable or definitely related to AuroShell particle infusion
次要结局
- Response in Targeted Tumors.(6 months)
研究者
研究点 (4)
Loading locations...
相似试验
终止
不适用
Efficacy Study of AuroLase Therapy in Subjects With Primary and/or Metastatic Lung TumorsPrimary or Metastatic Lung TumorsNCT01679470Nanospectra Biosciences, Inc.1
招募中
2 期
Combination of TATE and PD-1 Inhibitor in Liver CancerHepatocellular CarcinomaGastric CancerNCT03259867Teclison Ltd.54
已完成
不适用
Study of a Novel Microlens Array Device for Skin RejuvenationWrinklesScarsNCT02888626Cutera Inc.7
终止
1 期
A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid TumorsSolid TumorsNCT05129280Hoffmann-La Roche23
招募中
1 期
An Exploratory Clinical Study of BC006 in Patients With Advanced Solid TumorsAdvanced Solid Tumors (Including GCTTS)NCT05212896Dragonboat Biopharmaceutical Company Limited90